Avantor Inc. (AVTR) Stock Forecast & Price Target

Avantor is viewed positively because its turnaround is starting to show through in results, with VWR returning to +1.7% organic growth, better than expected, and BMP posting a smaller-than-feared -5.6% decline alongside double-digit order growth and a 1.1x book-to-bill. Management’s Revival actions—better service, e-commerce, branding, and operating execution—appear to be driving more than half of the improvement, while improving US pharma/biotech activity and early signs of healthier end markets add support. The company also raised FY26 organic revenue guidance to -0.5% to +0.5%, held adjusted EBITDA margin at 14.8% to 15.3%, and reaffirmed $500M to $550M in free cash flow, reinforcing confidence that operational gains are becoming durable.

Avantor is facing a fundamentally weaker outlook because its organic growth is expected to lag peers at roughly 1.5% to 2% from 2026 - 2028 versus about 5%, and that gap appears at least partly structural rather than cyclical. Demand normalization in scientific lab supply has taken years and repeatedly disappointed, while share losses remain a risk against Thermo Fisher and its operating model is exposed to lower-margin, distribution-heavy sales. Its adjusted operating margins have fallen to the low-teens from recent mid-teens, free cash flow guidance of $500M - $550M for 2026 looks difficult after $39M in Q1, and leverage plus tariff and geopolitical risks leave limited room for error.